Table 2.
Drug‐resistant mutations in patients who received nucleos(t)ide analogue monotherapies
| Drug usage* | Major mutational patterns | n | Drug usage | Major mutational patterns | n |
|---|---|---|---|---|---|
| LAM (n = 214/490) | ADV (n = 35/428) | ||||
| LAM‐R | M204I | 69 | ADV‐R | N236T | 11 |
| M204V + L180M | 54 | A181V | 10 | ||
| M204I + L180M | 44 | N236T + A181T | 5 | ||
| M204I/V + L180M | 15 | N236T + A181V | 4 | ||
| M204V + L180M + V173L | 15 | N236T + A181T/V | 2 | ||
| M204I/V + L180M + A181S | 3 | N236T + A181T/S | 1 | ||
| M204I/V + L180M + V173L | 3 | N236T + M250L | 1 | ||
| M204I + L180M + A181T | 2 | A181T/V | 1 | ||
| M204V | 1 | ETV (n = 0/73) | – | – | |
| M204I/V | 1 | ||||
| M204I + L180M + V173L | 1 | LdT (n = 5/18) | |||
| Coexist‐R | M204I + V173M + A181V | 1 | LAM‐R | M204I | 3 |
| ETV‐R | M204I + L180M + V173L + M250L | 1 | M204I + L180M | 1 | |
| M204I + M250L | 1 | M204I/V + L180M | 1 | ||
| M204V + T184S | 1 | ||||
| M204I/V + L180M + T184S | 1 | ||||
| M204V + L180M + S202G | 1 | ||||
LAM‐R, ADV‐R and ETV‐R represent lamivudine‐, adefovir‐ and entecavir‐resistant mutations, respectively. Coexist‐R represents coexistence of detectable LAM‐R/ETV‐R and ADV‐R in viral populations.
LdT, telbivudine.
*Each mono‐ or sequential/combined therapy lasted for ≥3 months.